Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 375

Sort by

Sort Order Select

Journal Articles

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Blood (2024) 144 (5): 541–551.

https://doi.org/10.1182/blood.2023023625

Published: 2024

Includes: Supplemental data

Journal Articles

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 982.

https://doi.org/10.1182/blood-2023-174901

Published: 2023

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Blood (2023) 142 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2023-184851

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, Martin Dreyling, Gianluca Gaidano, Nagesh Kalakonda, Eva Maria Gonzalez Barca, Anna Marina Liberati, Zsolt Nagy, Daniel Moik, Mirko Vukcevic, Aasim Amin, Abhishek Bakuli

Blood (2023) 142 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2023-174043

Published: 2023

Journal Articles

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Blood (2022) 140 (Supplement 1): 1281–1283.

https://doi.org/10.1182/blood-2022-166544

Published: 2022

Journal Articles

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Blood (2022) 140 (Supplement 1): 1765–1767.

https://doi.org/10.1182/blood-2022-159759

Published: 2022

Journal Articles

A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21 R110

Blood (2022) 140 (Supplement 1): 1800–1802.

https://doi.org/10.1182/blood-2022-165181

Published: 2022

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Blood (2022) 140 (Supplement 1): 9226–9227.

https://doi.org/10.1182/blood-2022-162416

Published: 2022

Journal Articles

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Blood (2022) 139 (5): 732–747.

https://doi.org/10.1182/blood.2021012386

Published: 2022

Includes: Supplemental data

Journal Articles

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Maria Cristina Puzzolo, Giulia Radice, Nadia Peragine, Maria Stefania de Propris, Paola Mariglia, Marco Vignetti, Antonella Vitale, Renato Bassan, Mario Annunziata, Gianluca Gaidano, Alessandro Rambaldi, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2021) 138 (22): 2290–2293.

https://doi.org/10.1182/blood.2021011822

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4440.

https://doi.org/10.1182/blood-2021-146585

Published: 2021

Journal Articles

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)

Stefano Molica, Luca Laurenti, Paolo Ghia, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Francesca Mauro, Anna Maria Frustaci, Daniele Vallisa, Fabrizio Pane, Giuliana Gualberti, Emilia Iannella, Paola Finsinger, Morena Caira, Paolo Sportoletti

Blood (2021) 138 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2021-148308

Published: 2021

Journal Articles

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 48.

https://doi.org/10.1182/blood-2021-148424

Published: 2021

Journal Articles

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Thomas Chatzikonstantinou, Lydia Scarfo, Christos Demosthenous, Jana Kotaskova, Gloria Iacoboni, Evangelia Minga, Dimitra Chammou, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, Shaimaa El-Ashwah, Francesca Bacchiarri, Mehreen Ali Khan, Thérèse Aurran, Anne Calleja, Ramona Cassin, Sofia Chatzileontiadou, Amy Christian, Rainer Claus, Rosa Collado, Marcos Daniel De Deus Santos, Zadie Davis, Maria Dimou, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Alicia Enrico, Alberto Fresa, Sara Galimberti, Rocío García-Serra, Isabel González-Gascón Y Marín, Alessandro Gozzetti, Valerio Guarente, Sean Harrop, Eleftheria Hatzimichael, Yair Herishanu, Luca Inchiappa, Michalis Iskas, Ozren Jaksic, Susanne R. Janssen, Elzbieta Kalicinska, Volkan Karakus, Arnon P. Kater, Bonnie Kho, Iliana Konstantinou, Thomas Longval, Maya Koren-Michowitz, Ioannis Kotsianidis, Robert J. Kreitman, Uttam Kumar Nath, Jorge Labrador, Deepesh Lad, Kamel Laribi, Ilana Levy, Alberto Lopez-Garcia, Juan Marquet Palomanes, Stanislava Maslejova, Carlota Mayor-Bastida, Fatiha Merabet, Biljana Mihaljevic, Ivana Milosevic, Fatima Miras, Riccardo Moia, Marta Morawska, Almudena Navarro-Bailón, David Oscier, Jacopo Olivieri, Tomáš Papajík, Maria Papaioannou, Cheyenne Pierie, Anna Puiggros, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Luana Schiattone, Omur Gokmen Sevindik, Yandong Shen, Martin Šimkovič, Svetlana Smirnova, Dina Sameh Soliman, Martin Špaček, Annett Schiwitza, Tamar Tadmor, Liat Tourjeman, Eric Tse, Andrea Visentin, Kristina Tomic, Michel Van Gelder, Theodoros P. Vassilakopoulos, Candida Vitale, George Vrachiolias, Vojin Vukovic, Zhenshu Xu, Lucrecia Yáñez, Munci Yagci, Mohamed A Yassin, Jana Zuchnicka, Maria K. Angelopoulou, Darko Antic, Bella V. Biderman, Mark Catherwood, Marta Coscia, Antonio Cuneo, Fatih Demirkan, Blanca Espinet, Gianluca Gaidano, Romain Guièze, Olga Kalashnikova, Luca Laurenti, Stephen Mulligan, Roberta Murru, Eugene A. Nikitin, Panayiotis Panayiotidis, Gerasimos Pangalis, Irina Panovska, Viola Maria Popov, Šárka Pospíšilová, Lukas Smolej, Paolo Sportoletti, Niki Stavroyianni, Constantine S. Tam, Livio Trentin, Marek Trněný, Francesc Bosch Albareda, Michael Doubek, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 138 (Supplement 1): 2635.

https://doi.org/10.1182/blood-2021-148738

Published: 2021

Journal Articles

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Manja Meggendorfer, Ferran Nadeu, Christian Brieghel, Helen Parker, Stamatia Laidou, Riccardo Moia, Davide Rossi, Mark Catherwood, Jana Kotaskova, Julio Delgado, Ana E Rodríguez-Vicente, Rocio Benito, Gian Matteo Rigolin, Silvia Bonfiglio, Lydia Scarfo, Mattias Mattsson, Zadie Davis, Ajay Gogia, Lata Rani, Panagiotis Baliakas, Cecilia Jylhä, Aron Skaftason, Inmaculada Rapado, Fatima Miras, Joaquin Martinez-Lopez, Javier de la Serna, Jesús M Hernández Rivas, Patrick Thornton, Maria Jose Larrayoz, María José Calasanz, Zoltán Mátrai, Csaba Bodor, Karin E. Smedby, Blanca Espinet, Anna Puiggros, Ritu Gupta, Lars Bullinger, Francesc Bosch, Bárbara Tazón, Fanny Baran-Marszak, David Oscier, Florence Nguyen-Khac, Thorsten Zenz, María José Terol, Antonio Cuneo, María Hernández-Sánchez, Sarka Pospisilova, Ken I Mills, Gianluca Gaidano, Carsten Utoft Niemann, Elías Campo, Jonathan C Strefford, Paolo Ghia, Kostas Stamatopoulos, Richard Rosenquist

Blood (2021) 138 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2021-150648

Published: 2021

Journal Articles

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Blood (2021) 138 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2021-146848

Published: 2021

Journal Articles

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

Francesca Arruga, Andrea Iannello, Nikolaos Ioannou, Alberto Maria Todesco, Marta Coscia, Riccardo Moia, Gianluca Gaidano, John N. Allan, Richard Furman, Tiziana Vaisitti, Alan G. Ramsay, Silvia Deaglio

Blood (2021) 138 (Supplement 1): 3718.

https://doi.org/10.1182/blood-2021-150183

Published: 2021

NARROW

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21 R110

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only